No Data
No Data
Nanjing Well Pharmaceutical Group (603351.SH): The subsidiary has obtained re-certification as a high-tech enterprise.
Gelonghui, February 6 - Nanjing Well Pharmaceutical Group (603351.SH) announced that its wholly-owned subsidiary Nanjing Well Biotechnology Co., Ltd. recently received the "High-tech Enterprise Certificate" jointly issued by the Jiangsu Provincial Department of Science and Technology, Jiangsu Provincial Department of Finance, and the Jiangsu Provincial Taxation Bureau of the State Administration of Taxation. This high-tech enterprise certification is a re-evaluation after the validity period of the original certificate expired.
Nanjing Well Pharmaceutical Group (603351.SH): has research related to liposomes.
Gelonghui, December 26th丨Nanjing Well Pharmaceutical Group (603351.SH) stated on the investor interaction platform that the company has research related to liposomes.
Well Pharmaceuticals: Weill Pharmaceuticals Third Quarter 2024 Report
Well Pharmaceuticals 2024 Third Quarter Report
Weil Pharmaceutical\'s announcement on the company\'s main operating data for the third quarter of 2024
Nanjing Well Pharmaceutical Group (603351.SH) executive Zou Jianguo reduced his shareholding by 9300 shares.
Nanjing Well Pharmaceutical Group (603351.SH) announced that as of September 11, 2024, the time for this shareholding plan...